SERTAD4 (SERTA domain containing 4) is a transcriptional regulator that plays critical roles in cardiac fibrosis and skeletal development. The protein is primarily localized to the nucleoplasm and cytoplasm, functioning as a downstream target of BRD4 in cardiac fibroblasts 1. In cardiac pathology, SERTAD4 expression is induced by TGF-β signaling through a p38 MAPK-dependent pathway, promoting cardiac fibroblast activation and extracellular matrix production 1. Global knockout of Sertad4 in mice subjected to myocardial infarction resulted in attenuated cardiac remodeling, reduced hypertrophy and ventricular dilation, and preserved systolic function 2. Beyond cardiac function, SERTAD4 contributes to skeletal development, with variants near the gene associated with non-syndromic cleft lip with or without cleft palate 3, and zebrafish knockdown models showing mandibular deficiency and developmental abnormalities 3. Systems genetics analyses have identified SERTAD4 as a causal gene for human bone mineral density GWAS associations 4. In cancer contexts, SERTAD4 shows altered expression patterns, being upregulated in breast cancer where it correlates with poor prognosis 5, while being downregulated in colorectal cancer where it may inhibit bacterial colonization 6.